Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

2.6K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
2.6K
Protein-protein Interfaces02:04

Protein-protein Interfaces

12.4K
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
12.4K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

5.9K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
5.9K
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

4.7K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
4.7K
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

2.3K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.3K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

469
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
469

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

GHF-ACL: A novel contrastive learning framework with multi-order graph structures for herb-disease association prediction.

PLoS computational biology·2026
Same author

Identification and characterization of lncRNA-stemness-immune regulatory patterns.

Briefings in bioinformatics·2026
Same author

Hypoxia-Associated Alternative Polyadenylation of CARM1 and Tumor Microenvironment Alterations in Non-Small Cell Lung Cancer.

Genes·2026
Same author

EP-YOLO: An Enhanced Lightweight Model for Micro-Pest Detection in Agricultural Light-Trap Environments.

Sensors (Basel, Switzerland)·2026
Same author

DECODE: deep learning-based common deconvolution framework for various omics data.

Nature methods·2026
Same author

DL-GapFilling: a novel deep learning framework for improved plant genome gap filling.

Briefings in bioinformatics·2026

Related Experiment Video

Updated: May 20, 2025

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.1K

Relational similarity-based graph contrastive learning for DTI prediction.

Jilong Bian1, Hao Lu1, Limin Wei1

  • 1College of Computer and Control Engineering, Northeast Forestry University, Harbin 150040, Heilongjiang, China.

Briefings in Bioinformatics
|March 24, 2025
PubMed
Summary

This study introduces a new method, RSGCL-DTI, to improve drug-target interaction (DTI) prediction by combining structural and relational features. This approach enhances drug repurposing accuracy and outperforms existing models.

Keywords:
DTI predictiongraph contrastive learningrelational similarity networkstructural features

More Related Videos

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

11.6K
Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

18.4K

Related Experiment Videos

Last Updated: May 20, 2025

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.1K
High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

11.6K
Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

18.4K

Area of Science:

  • Computational Biology
  • Bioinformatics
  • Drug Discovery

Background:

  • Accurate drug-target interaction (DTI) prediction is crucial for efficient drug repurposing.
  • Existing deep learning methods for DTI prediction often focus solely on structural or relational features, limiting performance.
  • Integrating diverse feature types can significantly enhance DTI prediction accuracy.

Purpose of the Study:

  • To develop an advanced DTI prediction model that leverages both structural and relational features of drugs and proteins.
  • To improve the accuracy and efficiency of drug repurposing through enhanced DTI prediction.
  • To introduce a novel graph contrastive learning approach for feature extraction in DTI prediction.

Main Methods:

  • Proposed Relational Similarity-based Graph Contrastive Learning for DTI prediction (RSGCL-DTI).
  • Extracted inter-protein and inter-drug relational features using graph contrastive learning on a heterogeneous drug-protein interaction network.
  • Combined extracted relational features with structural features from D-MPNN and CNN for comprehensive feature representation.

Main Results:

  • The RSGCL-DTI model demonstrated superior performance compared to eight state-of-the-art baseline models across four benchmark datasets.
  • The proposed method showed robust performance on imbalanced datasets, a common challenge in DTI prediction.
  • RSGCL-DTI exhibited excellent generalization capabilities, effectively predicting interactions for unseen drug-protein pairs.

Conclusions:

  • Combining graph contrastive learning-derived relational features with structural features significantly enhances DTI prediction.
  • RSGCL-DTI offers a more accurate and reliable approach for drug repurposing.
  • The model's strong performance and generalization ability highlight its potential for real-world drug discovery applications.